PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Acid suppression (Adults) (Omeprazole - Acid suppression (Adults))

Records returned : 15 (on 23 Nov 2024 at 08:07:18). .

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
01.03.05
Omeprazole
Acid suppression (Adults)
Green
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
1st line for patients with no swallowing difficulties.
01.03.05
Acid suppression (Adults)
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
Important
Omeprazole or lansoprazole capsules are 1st-line. Pantoprazole or rabeprazole tablets are 2nd-line for patients without swallowing difficulties (suitable for patients that cannot have animal-derived products).
01.03.05
Acid suppression (Adults)
Non Formulary
Formulations :
  • Oral suspension
  • Oro-dispersible
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
Important
Omeprazole capsules can be opened for patients with swallowing difficulties. Lansoprazole oro-dispersible tablets are 1st-line for patients with enteral feeding tubes
01.03.01
Famotidine
Acid suppression (Adults)
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Preferred
01.03.05
Lansoprazole
Acid suppression (Adults)
Green
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
1st line for patients with no swallowing difficulties. 2nd line for adults with swallowing difficulties / feeding tubes - capsules can be opened.
01.03.05
Acid suppression (Adults)
Green (see narrative)
Formulations :
  • Oro-dispersible
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
1st line in adults with swallowing difficulties. 1st line for patients with enteral feeding tubes.
01.03.05
Esomeprazole
Acid suppression (Adults)
Green (see narrative)
Formulations :
  • Granules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Lansoprazole oro-dispersible 1st-line. Esomeprazole is 3rd-line. Restricted to patients with swallowing difficulties or with large bore enteral feeding tube when other options are not clinically appropriate. Do not use in tubes less than 6F.
01.03.01
Nizatidine
Acid suppression (Adults)
Green (see narrative)
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
For use where a PPI is not suitable and an H2RA is indicated. For doses of 300mg, please prescribe 2x150mg as this is considerably more cost effective.
01.03.01
Cimetidine
Acid suppression (Adults)
Green (see narrative)
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Important
Reserve for use where a PPI AND and other H2RAs are not suitable OR where a liquid preparation is required. Check for drug interactions.
01.03.05
Pantoprazole
Acid suppression (Adults)
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
2nd line in adults without swallowing difficulties. (Suitable for patients that cannot have animal-derived products / capsules.)
01.03.05
Rabeprazole sodium
Acid suppression (Adults)
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
2nd line in adults without swallowing difficulties. (Suitable for patients that cannot have animal-derived products / capsules.)
01.03.05
Esomeprazole
Acid suppression (Adults)
Green (see narrative)
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Lansoprazole capsules are the preferred option. Esomeprazole 40mg restricted to short-term use or for Zollinger-Ellison syndrome.
01.03.05
Acid suppression (Adults)
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
01.03.01
Ranitidine
Acid suppression (Adults)
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
U
01.03.05
Lansoprazole
Acid suppression (Adults)
Non Formulary
Formulations :
  • Liquid
  • Oral solution
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Lansoprazole oro-dispersible tablets are 1st-line for adults with swallowing dificulties or enteral feeding tubes.
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More